Table 4. Outcomes according to pre-DLI... | American Society of Hematology

Table 4.

Outcomes according to pre-DLI factors and the ICD: univariate analysis

Factors^4-150	GVHD^4-151		Myelosuppression^‡		Response^‡		Survival			FFS			DLI-RM
Factors^4-150	%	P	%	P	%	P	% at 1 y	% at 3 y	P	% at 1 y	% at 3 y	P	% at 1 y	% at 3 y	P
Sex of donor
Male	38	<.01	19	.92	70	.64	82	71	<.01	75	54	.10	9	13	.01
Female	58		19		67		70	55		67	48		15	21
Sex match with the donor
Matched	36	<.01	18	.58	67	.43	78	68	.52	74	52	.81	8	13	.33
Mismatched	57		20		71		77	63		70	52		13	17
Phase at SCT
First chronic phase	47	.04	19	.76	75	<.01	83	73	<.01	78	59	<.01	10	15	.26
More advanced	32		17		48		57	38		52	28		15	19
T-cell depletion at SCT
No	40	.10	16	.14	63	<.01	74	64	.44	69	47	.01	12	15	.35
Yes	50		22		80		82	68		78	62		10	17
Interval SCT-first infusion
Fewer than 2 y	48	.33	19	.64	65	.12	70	58	<.01	64	45	.01	13	17	.49
More than 2 y	42		17		73		83	72		79	59		9	14
Date of DLI
1988-1995	55	<.01	22	.07	69	.67	75	60	.03	70	51	.41	11	19	.19
1996-1998	32		14		71		80	72		76	54		11	13
Stage of relapse at DLI
Molecular/cytogenetic	32	.01	12	<.01	87	<.01	87	81	<.01	85	68	<.01	8	9	.04
Hematologic	51		19		71		85	71		80	55		10	17
Transformed	49		28		37		39	27		31	19		28	33
ICD^‡
Group A^4-153	26	<.01	10	.01	78	.48	94	84	<.01	86	66	<.01	2	5	<.01
Group B^4-155	53		23		73		75	63		67	57		13	20
Group C^4-154	62		24		70		65	58		54	45		18	22

Factors^4-150	GVHD^4-151		Myelosuppression^‡		Response^‡		Survival			FFS			DLI-RM
Factors^4-150	%	P	%	P	%	P	% at 1 y	% at 3 y	P	% at 1 y	% at 3 y	P	% at 1 y	% at 3 y	P
Sex of donor
Male	38	<.01	19	.92	70	.64	82	71	<.01	75	54	.10	9	13	.01
Female	58		19		67		70	55		67	48		15	21
Sex match with the donor
Matched	36	<.01	18	.58	67	.43	78	68	.52	74	52	.81	8	13	.33
Mismatched	57		20		71		77	63		70	52		13	17
Phase at SCT
First chronic phase	47	.04	19	.76	75	<.01	83	73	<.01	78	59	<.01	10	15	.26
More advanced	32		17		48		57	38		52	28		15	19
T-cell depletion at SCT
No	40	.10	16	.14	63	<.01	74	64	.44	69	47	.01	12	15	.35
Yes	50		22		80		82	68		78	62		10	17
Interval SCT-first infusion
Fewer than 2 y	48	.33	19	.64	65	.12	70	58	<.01	64	45	.01	13	17	.49
More than 2 y	42		17		73		83	72		79	59		9	14
Date of DLI
1988-1995	55	<.01	22	.07	69	.67	75	60	.03	70	51	.41	11	19	.19
1996-1998	32		14		71		80	72		76	54		11	13
Stage of relapse at DLI
Molecular/cytogenetic	32	.01	12	<.01	87	<.01	87	81	<.01	85	68	<.01	8	9	.04
Hematologic	51		19		71		85	71		80	55		10	17
Transformed	49		28		37		39	27		31	19		28	33
ICD^‡
Group A^4-153	26	<.01	10	.01	78	.48	94	84	<.01	86	66	<.01	2	5	<.01
Group B^4-155	53		23		73		75	63		67	57		13	20
Group C^4-154	62		24		70		65	58		54	45		18	22

Factors such as patient age, donor type, and GVHD after SCT are left off because they were not related with any of the outcomes.

Acute GVHD grades II to IV and/or chronic GVHD.

Definition in “Patients and methods.”

Patients with ICD less than 0.21 MNC × 10⁸/kg.

Patients with ICD dose from 0.21 to 2.0 MNC × 10⁸/kg.

Patients with initial cell dose more than 2.0 MNC × 10⁸/kg.